Bendigo Health

bendigohealth.org.au

With more than 3500 staff and covering an area a quarter of the size of Victoria, Bendigo Health Care Group (commonly known as Bendigo Health) is an expanding regional health service offering the advantages of city life combined with the beauty and freedom that comes from living in a regional area. Bendigo Health, around 665 bed service*, treated almost 42,000 inpatients, triaged more than 50,000 emergency attendees and welcomed more than 1,400 new born babies in the reporting period July 1, 2015 to June 30, 2016.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

SALIPRO BIOTECH RECEIVES EUROPEAN PATENT FOR ANTIGEN PRODUCTION

Salipro Biotech | February 09, 2022

news image

Swedish biotech company Salipro Biotech AB announced that the European Patent Office has granted a further European Patent to the company, No. EP 3 043 814 B1 entitled "Antigen and method for production thereof", following the approval of the US-member of this patent family already in 2018 under US Patent 10,159,729 B2. The patents cover the composition-of-matter, methods and uses of the company's novel antigen technology, strengthening Salipro Biotech's proprietary platform te...

Read More

NOVARTIS TAPS ORIONIS TO PURSUE 'HISTORICALLY ELUSIVE TARGETS'

FierceBiotech | March 06, 2020

news image

Novartis has entered into a four-year research collaboration with Orionis Biosciences. The agreement tasks Orionis with applying its technologies to “historically elusive targets” in multiple therapeutic areas. Orionis has been around since 2015 but kept a low profile over most of that time. The transatlantic biotech used its time flying below the radar to establish two platforms, one focused on cytokines and another for “genome-scale drug discovery,” and to use them to g...

Read More

INDUSTRIAL IMPACT

GLUBIO COMPLETES SERIES A+ FINANCING OF $22 MILLION TO ADVANCE THE DEVELOPMENT OF NOVEL TPD DRUGS

GluBio Therapeutics Inc | August 02, 2022

news image

GluBio Therapeutics, a biotech company focused on developing novel targeted protein degradation (TPD) drugs, recently announced the completion of Series A+ financing of $22 million. This round is led by Qiming Venture Partners and joined by Lilly Asia Ventures and Kaitai Capital, bringing the total capital raised to nearly $90 million since its establishment in March, 2021. The investment will help advance two molecular glue degraders with best-in-class potential into the clinic f...

Read More

ROCHE LAUNCHES EXOME AND CUSTOM KAPA TARGET ENRICHMENT PORTFOLIO TO EMPOWER CLINICAL RESEARCHERS

Roche | May 13, 2020

news image

KAPA HyperExome is a state-of-the-art whole exome research panel with improved performance over the on-market SeqCap portfolio, providing improved coverage and uniformity. The KAPA Target Enrichment portfolio empowers clinical researchers to process more sa...

Read More
news image

MEDTECH

SALIPRO BIOTECH RECEIVES EUROPEAN PATENT FOR ANTIGEN PRODUCTION

Salipro Biotech | February 09, 2022

Swedish biotech company Salipro Biotech AB announced that the European Patent Office has granted a further European Patent to the company, No. EP 3 043 814 B1 entitled "Antigen and method for production thereof", following the approval of the US-member of this patent family already in 2018 under US Patent 10,159,729 B2. The patents cover the composition-of-matter, methods and uses of the company's novel antigen technology, strengthening Salipro Biotech's proprietary platform te...

Read More
news image

NOVARTIS TAPS ORIONIS TO PURSUE 'HISTORICALLY ELUSIVE TARGETS'

FierceBiotech | March 06, 2020

Novartis has entered into a four-year research collaboration with Orionis Biosciences. The agreement tasks Orionis with applying its technologies to “historically elusive targets” in multiple therapeutic areas. Orionis has been around since 2015 but kept a low profile over most of that time. The transatlantic biotech used its time flying below the radar to establish two platforms, one focused on cytokines and another for “genome-scale drug discovery,” and to use them to g...

Read More
news image

INDUSTRIAL IMPACT

GLUBIO COMPLETES SERIES A+ FINANCING OF $22 MILLION TO ADVANCE THE DEVELOPMENT OF NOVEL TPD DRUGS

GluBio Therapeutics Inc | August 02, 2022

GluBio Therapeutics, a biotech company focused on developing novel targeted protein degradation (TPD) drugs, recently announced the completion of Series A+ financing of $22 million. This round is led by Qiming Venture Partners and joined by Lilly Asia Ventures and Kaitai Capital, bringing the total capital raised to nearly $90 million since its establishment in March, 2021. The investment will help advance two molecular glue degraders with best-in-class potential into the clinic f...

Read More
news image

ROCHE LAUNCHES EXOME AND CUSTOM KAPA TARGET ENRICHMENT PORTFOLIO TO EMPOWER CLINICAL RESEARCHERS

Roche | May 13, 2020

KAPA HyperExome is a state-of-the-art whole exome research panel with improved performance over the on-market SeqCap portfolio, providing improved coverage and uniformity. The KAPA Target Enrichment portfolio empowers clinical researchers to process more sa...

Read More